LENVIMA 4 mg, hard capsule 30 capsules
Active ingredients: Lenvatinib, Lenvatinib mesylate
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule30 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LENVIMA 4 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 3 plaquette(s) polyamide aluminium PVC-Aluminium de 10 gélule(s)
- Marketing authorisation holder
- EISAI (ROYAUME-UNI)
- Reimbursement according to BDPM
- 100%
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- Cancer de la thyroïde ; JOURNAL OFFICIEL ; 10/01/17
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 14 Jan 2017
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62093424CIP73001894CIP133400930018941Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LENVATINIBgélule | 4 mg · une gélule | FT |
| MÉSILATE DE LENVATINIBgélule | 4,90 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The published catalog does not list other packages of similar medicines.